Semaglutide Should Transform Novo Nordisk's Prospects, CSO Says
Executive Summary
Novo Nordisk's investigational GLP-1 agonist semaglutide promises to elevate the Danish group's product offering and market position, its CSO says in an interview with Scrip.
You may also be interested in...
Novo Nordisk CSO Outlines Obesity R&D Strategy, Calls Condition "Ticking Time Bomb"
Novo Nordisk' obesity pipeline consists of projects addressing both appetite reduction and energy expenditure, with GLP-1 semaglutide topping the list, its CSO says in an interview with Scrip.
Novo's Semaglutide: Retinopathy Warning Unlikely To Dim Commercial Prospects
Sponsor's proposal for a label warning, but not a black box, on retinopathy risk with the once-weekly GLP-1 agonist finds support from a US FDA advisory committee, which overwhelming endorsed approval for treatment of type 2 diabetes on the basis of robust glycemic control efficacy data and a strong cardiovascular safety profile.
Novo's Semaglutide Outperforms Lilly's Trulicity In SUSTAIN 7
Lilly's performance-based plans for Trulicity may be harder to sustain if Novo's competing once-weekly GLP-1 agonist semaglutide is approved in December, following superiority in a head-to-head diabetes study.